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Abstract. Patients with diabetes are vulnerable to delayed 
bone fracture healing or pseudoarthrosis. Chronic sustained 
hyperglycemia, reactive intermediate derivatives of glucose 
metabolism, such as methylglyoxal (MGO), and advanced 
glycation end-products (AGEs) are implicated in diabetic 
complications. In the present study, it was examined whether 
MGO is able to cause disturbed bone healing in diabetes. 
Diabetes was induced in male mice by injection of strep-
tozotocin (50 mg/kg) for 5 days. A bone defect (1.0-mm 
diameter) was created in the left distal femur, and bone repair 
was assessed from an examination of computed tomography 
scans. ST2 cells were exposed to MGO (0-400 µM) to inves-
tigate osteoblastic differentiation, cell viability, and damage. 
Consequently, blood glucose and hemoglobin A1c levels in 
diabetic mice were determined to be 493±14.1 mg/dl and 
8.0±0.05%, respectively. Compared with non-diabetic control 
mice, diabetic mice exhibited markedly delayed bone 
healing, with increased levels of the MGO-derived AGEs, 
Nε-(carboxymethyl)-lysine and Nδ-(5-hydro-5-methyl-4-imida
zolone-2-yl)-ornithine, in the sera and femurs. MGO inhibited 
the osteoblastic differentiation of ST2 cells in a dose-dependent 
manner, and markedly decreased cell proliferation through 
cytotoxicity. In conclusion, MGO has been demonstrated to 
cause impaired osteoblastic differentiation and delayed bone 
repair in diabetes. Therefore, detoxification of MGO may be 
a potentially useful strategy against bone problems in patients 
with diabetes.
Introduction
Osteoporosis is a bone condition characterized by low bone 
mass, increased fragility, decreased bone quality, and an 
increased fracture risk (1). It often becomes symptomatic 
when a fracture occurs accidentally. The incidence of frac-
tures is known to increase with age, consequently leading 
to a high mortality rate and an overall functional decline in 
elder patients with osteoporosis. It has been reported that the 
mortality rate during the first year following a hip fracture is 36 
and 21% for men and women, respectively (2). As with aging, 
poor glycemic control in diabetes is a well-known risk factor 
for bone fracture. For example, patients with type 1 diabetes 
are reported to have a 6.9-fold higher risk for hip fracture, 
with decreased bone mineral density (BMD) (1). There is also 
increasing evidence supporting an association between type 2 
diabetes and increased fracture risk (2-4). The Rotterdam 
study revealed that individuals with type 2 diabetes had a 69% 
increased fracture risk compared with those without diabetes, 
despite having higher BMD (5). In addition, impaired frac-
ture healing is also demonstrated in diabetes (2-4,6,7). Bone 
fracture healing in diabetes was reported to be prolonged by 
87% with a 3.4-fold higher risk of delayed union, non-union, 
redislocation, or pseudoarthrosis (3,8,9), which are commonly 
observed in type 1 and type 2 diabetes. These bone prob-
lems, such as osteoporosis and delayed fracture healing, are 
thus recognized as additional complications of longstanding 
diabetes.
Several mechanisms, including insulin insufficiency, 
hyperglycemia, and oxidative stress, are considered to 
delay fracture healing in type 1 and type 2 diabetes via the 
reduction of osteoblast differentiation, increased osteoclast 
activity, and induction of apoptosis in chondrocytes and osteo-
blasts (7,10-12). Of these, chronic and sustained hyperglycemia 
is known to enhance the glycation reaction, and ultimately 
results in the formation of advanced glycation end-products 
(AGEs). The accumulation of AGEs has been associated with 
diabetic complications, as well as various aging-associated 
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diseases, including Alzheimer's disease and osteoporosis. 
Notably, AGEs are reported to inhibit osteoblastic differentia-
tion and to induce apoptosis in osteoblasts, leading to decreased 
osteoblast numbers and impaired bone formation (13,14). 
Methylglyoxal (MGO) is a cell-permeant molecule, highly 
deleterious and the most potent glycating agent for very rapid 
generation of AGEs in cellular macromolecules (15,16). In the 
glycation reaction, MGO is up to 20,000-fold more reactive 
compared with glucose. The most important endogenous 
source of MGO is the fragmentation of the triose phosphates, 
glyceraldehyde 3-phosphate and dihydroxyacetone phosphate, 
via the glycolytic pathway (17,18). MGO may also be produced 
as a by-product of protein and fatty acid metabolism (19-21). 
MGO formation is known to be increased in patients with 
diabetes (22). Therefore, MGO may be implicated in affecting 
bone-healing processes in diabetes; however, direct evidence 
has not been provided using an in vivo bone-healing model.
In the present study, the effect of MGO on the differentia-
tion, growth and cytotoxicity of osteoblastic cells in vitro was 
examined, and the accumulation of MGO-derived AGEs in the 
sera and femurs was measured using an in vivo bone defect 
mouse model with or without streptozotocin (STZ)-induced 
diabetes.
Materials and methods
Cell culture. Mouse ST2 cells (Riken Cell Bank, Tsukuba, 
Japan) were cultured in α-minimum essential medium 
(5.5 mmol/l glucose; Wako Pure Chemical Industries, Osaka, 
Japan), supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin, and 100 µg/ml streptomycin in 5% CO2 at 37˚C. 
To induce osteoblastic differentiation in the ST2 cells, 10 mM 
β-glycerophosphate, 0.1 µM dexamethasone, and 50 µM 
ascorbic acid were added to the cell culture medium. For the 
assays, 0, 50, 200, or 400 µM MGO (Sigma-Aldrich; Merck 
KGaA, Darmstadt, Germany) was added to the differentiation 
medium, and the medium was changed every other day.
Alkaline phosphatase (ALP) activity assay. ALP activity in 
the ST2 cells was determined 7 days after the induction of 
osteoblastic differentiation, using a TRACP & ALP Assay kit 
(Takara Bio, Inc., Otsu, Japan), according to the manufacturer's 
protocol.
Mineralization assay. Calcium deposition was evaluated 
28 days after differentiation of the ST2 cells. An In Vitro 
Osteogenesis Assay kit (EMD Millipore, Billerica, MA, USA) 
was used for alizarin red staining and quantitative analysis, 
following the manufacturer's protocols.
Cell proliferation assay. ST2 cell proliferation was assayed by 
the cell-based WST-1 method using a Cell Proliferation Assay 
kit (Chemicon®; EMD Millipore), at 7 and 14 days after the 
induction of differentiation, according to the manufacturer's 
protocol.
Cytotoxicity assay. ST2 cells were seeded on 6-well plates at a 
density of 105 cells/well. After 48 h, osteoblastic differentiation 
was induced by the addition of 0, 50, 200, or 400 µM MGO. 
After 72 h, release of the enzyme, lactate dehydrogenase 
(LDH), was assayed using a Non-Radioactive Cytotoxicity 
assay (Promega Corp., Madison, WI, USA), according to the 
manufacturer's protocol.
Experimental animals and induction of diabetes. Male 
C57BL/6J mice (weight, 21 g) at 6 weeks of age were purchased 
from Charles River Japan, Inc. (Yokohama, Japan), and 
acclimatized for 1 week prior to the start of the experiment. 
To induce diabetes, the mice (n=37) were intraperitoneally 
injected with STZ (50 mg/kg body weight) daily for 5 days, 
according to the Animal Models of Diabetic Complications 
Consortium (AMDCC) protocols. By contrast, sodium citrate 
buffer was injected into control mice (n=28). After 3 weeks, 
non-fasting blood glucose levels were measured using a 
glucometer (Glutest Ace, Sanwa Kagaku, Japan), using whole 
blood obtained from the tail vein. Mice with blood glucose 
levels >300 mg/dl were considered to be diabetic. Hemoglobin 
A1c (HbA1c) was measured in tail vein blood using a DCA 
Vantage analyzer (Siemens Healthineers, Erlangen, Germany). 
Mice were maintained under standard cage conditions (24˚C; 
12-h light/dark cycle, lights on at 8:45 a.m.) with sawdust 
bedding, and access to food and water ad libitum. All animal 
experiments were approved by the Committee on Animal 
Experimentation of Kanazawa University, and performed 
in accordance with the Fundamental Guidelines for Proper 
Conduct of Animal Experiment and Related Activities in 
Academic Research Institutions under the jurisdiction of 
the Ministry of Education, Culture, Sports, Science, and 
Technology of Japan.
Induction of drill‑hole injury in the femur. Under anesthesia 
with a mixture of medetomidine (0.3 mg/kg), midazolam 
(4.0 mg/kg) and butorphanol (5.0 mg/kg), a straight, longitu-
dinal skin incision (5 mm) was made in the distal femur of the 
mice, and the periosteal membrane was subsequently stripped 
away, following muscle splitting, to expose the bone surface. 
A drill-hole injury was then introduced by inserting a drill bit 
with a diameter of 0.9 mm fixed to a finger handle at the medial 
portion of the diaphysis of the left femur, 5 mm above the 
knee joint. The hole was drilled through the collateral cortical 
bone and bone marrow, and thus a round defect measuring 
~1.0 mm in diameter was made. The hole was irrigated with 
saline solution to prevent thermal necrosis of the margins. The 
incised skin was subsequently sutured in a sterile manner, and 
anesthesia was discontinued. During the surgery, the body 
temperature was maintained at 37˚C using a heating pad.
Computed tomography (CT) scanning. Mice were anesthetized 
using the aforementioned procedure, and femurs were scanned 
using an X-ray CT system (Latheta LCT-200; Hitachi Aloka 
Medical, Tokyo, Japan) at 3, 7, 10, and 14 days after bone injury. 
The healing process in the bone defect area was evaluated 
using suitable analysis software (AzeWin; AZE, Ltd., Tokyo, 
Japan). Images were processed in a multiplanar reconstruction, 
according to oblique coronal planes, maintaining working axes 
parallel to the center line of the bone defect. CT values at the 
area of bone defect were calculated at each phase.
Measurement of MGO‑derived AGEs. Collected serum 
was stored at ‑80˚C prior to analysis. Serum levels of 
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the MGO-derived AGEs, Nε-(carboxymethyl)-lysine 
(CML) and N δ- (5-hydro-5-methyl- 4 -imidazolone-
2-yl)-ornithine (MG-H1), were measured using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), 
as previously described (23). Briefly, low‑molecular‑weight 
fractions (<3,000 kDa) in the serum (50 µl) were separated 
using a Vivaspin® centrifugal concentrator (Vivaspin® 
500; Sartorius Stedim Biotech, Goettingen, Germany) 
according to the manufacturer's protocol, and then reduced 
with sodium borohydride (NaBH4) (Sigma-Aldrich; Merck 
KGaA). Standard [2H2]CML (0.01 nmol) and [2H2]MG-H1 
(0.01 nmol) (PolyPeptide Laboratories, Strasbourg, France), 
and [13C6]lysine (5 nmol) (Cambridge Isotope Laboratories, 
Inc., Tewksbury, MA, USA), were added to the reduced 
samples. The prepared samples were subsequently passed 
through a Strata-X-C column (Phenomenex, Torrance, CA, 
USA) and assayed by LC-MS/MS using a TSQ Vantage 
triple-stage quadrupole mass spectrometer (Thermo Fisher 
Scientific, Waltham, MA, USA). AGE structures, lysine, 
and the standards were detected using electrospray positive 
ionization-mass spectrometric multiple reaction monitoring.
The femur samples were cleaned of periosteal membrane 
and bone marrow, and subsequently frozen and pulverized 
in liquid nitrogen, as previously described (24). The levels of 
CML and MG‑H1 in the specimens were also quantified by 
LC‑MS/MS serum sample measurement (24). Briefly, bone 
powder was demineralized with 0.5 M EDTA in 50 mM Tris 
buffer (pH 7.4) for 96 h at 4˚C. Demineralized bone residues 
were reduced at room temperature with NaBH4. Specimens 
were hydrolyzed in 6 M HCl at 100˚C for 18 h. The prepared 
samples were then assayed using [2H3]hydroxyproline (C/D/N 
Isotopes Inc., Quebec, Canada).
Statistical analysis. Data are expressed as the mean ± stan-
dard error of the mean. P-values were calculated using a 
two-tailed Student's t-test for pairwise comparisons, and 
one-way analysis of variance followed by Bonferroni's test for 
multiple comparisons (Ekuseru-Toukei 2012 software; SSRI, 
Tokyo, Japan), unless otherwise stated. P<0.05 was considered 
to indicate a statistically significant difference.
Results
Bone defect repair in STZ‑induced diabetic mice. Compared 
with non-diabetic control mice, the diabetic mice exhibited 
marked decreases in body weight (27±0.3 vs. 23±0.3 g) and 
significantly increased levels of non-fasting blood glucose 
(140±3.8 vs. 493±14.1 mg/dl) and HbA1c (4.0±0.05% 
vs. 8.0±0.16%; control vs. diabetic mice, respectively) at 
3 weeks after the STZ injection (P<0.05; Table I). After 
confirming the presence of overt diabetic conditions in the 
mice, a drill-hole injury (1.0 mm in diameter) was introduced 
at the medial portion of the diaphysis of the left femur (5 mm 
above the knee joint) to check the recovery rate from bone 
injury. The healing process in the bone defect area was subse-
quently evaluated using CT scanning at days 3, 7, 10 and 14 
after injury (Fig. 1A). CT imaging of the bone defect lesions 
revealed no significant differences in ossification between 
the non-diabetic and the diabetes-induced mice at the early 
healing stage on day 3 (Fig. 1A and B). However, repair of the 
damaged site on the femur was significantly delayed at days 7 
and 10 in diabetic mice, corresponding to intramembranous 
bone formation, chondrogenesis and early endochondral bone 
phases. In non-diabetic controls, recovery peaked at day 10, 
and reached a plateau thereafter (Fig. 1A and B).
Diabetes altered bone quality through increased accumulations 
of CML and MG‑H1. Subsequently, the accumulation of 
MGO-derived AGEs, CML, and MG-H1 in sera and femurs 
under diabetic conditions was investigated. In the sera from 
diabetic mice, the levels of CML and MG‑H1, as quantified 
by LC‑MS/MS, were significantly increased compared with 
those in non-diabetic controls (Fig. 2A). Similarly, higher 
levels of femur CML and MG-H1 were observed in diabetic 
mice compared with control mice (Fig. 2B). These findings 
suggested that MGO generated under diabetic conditions is 
able to affect bone defect healing in our animal model.
Effect of MGO on in vitro osteoblastic differentiation of ST2 
cells. Impairment of osteoblastic differentiation is an impor-
tant factor in the pathogenesis of detrimental bone repair. To 
address the effect of MGO on osteoblastic differentiation, the 
mouse stromal ST2 cell line was used, which is an established 
cell culture model characterized by its potency to differen-
tiate into cells with the typical characteristics of osteoblasts, 
and the formation of mineralized nodules (25,26). Using 
ALP activity as an osteoblastic differentiation marker, ST2 
cells were cultured in induction media with MGO at a final 
concentration of 0, 50, 200, or 400 µM. MGO exposure for 
7 days decreased ALP activity in a dose-dependent manner, 
and significantly inhibited osteoblastic differentiation of ST2 
cells at 200 and 400 µM MGO (P<0.05 and P<0.01, respec-
tively; Fig. 3A and B). Matrix mineralization, the final step of 
osteoblast differentiation, serves a critical role in maintaining 
the mechanical integrity of bone tissues.
Subsequently, the effects of MGO on mineralization were 
examined using alizarin red staining after 28 days of differ-
entiation. In the presence of MGO, dose-dependent decreases 
in calcium deposition in ST2 cells were observed, which were 
statistically significant at 200 and 400 µM MGO (P<0.05 and 
P<0.01, respectively; Fig. 3C and D). These results indicated that 
exposure to MGO led to disrupted osteoblastic differentiation.
Effect of MGO on cell viability and cytotoxicity in ST2 cells. 
Subsequently, it was examined whether MGO may affect 
Table I. Diabetic status of STZ-induced mice.
 Control STZ-induced
Measurement (n=28) (n=37)
Body weight (g) 27±0.3 23±0.3a
Blood glucose (mg/dl) 140±3.8 493±14.1a
HbA1c (NGSP, %) 4.0±0.05 8.0±0.16a
aP<0.05; the data are expressed as mean ± standard error of the mean. 
NGSP, National Glycohemoglobin Standardization Program; STZ, 
streptozotocin.
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cell viability and proliferation, and induce cytotoxicity in 
ST2 cells. Cell proliferation assays clearly demonstrated that 
400 µM MGO severely inhibited ST2 cell growth during the 
observation period, and lower concentrations of MGO (50 and 
200 µM) could significantly, although to a much lesser extent, 
inhibit proliferation at day 7 of cultivation (Fig. 4A). However, 
no significant difference was observed among cells exposed 
to 0, 50, and 200 µM MGO at day 14, which had already 
achieved confluency (Fig. 4A). Finally, ST2 cell damage was 
examined using an LDH assay, which monitored release of 
the cytoplasmic enzyme into the culture media. As expected, 
a significant (P<0.01) and dramatic increase in LDH leakage 
was seen with 400 µM MGO (Fig. 4B), whereas 50 µM MGO 
elicited no effect, and 200 µM slightly induced cytotoxicity in 
cultured ST2 cells (Fig. 4B).
Discussion
In the present study, it has been demonstrated that MGO 
may exert a role in inhibiting osteoblastic differentiation, 
mineralization, and proliferation of mouse stromal ST2 cells 
(Figs. 3 and 4). MGO was also found to increase cell damage 
at higher concentrations (≥ 200 µM) (Fig. 4B). Concentrations 
of MGO in the range 50-400 µM were used in these experi-
ments, as described previously (27). The concentration of 
MGO that occurs in vivo is still under debate. It has been 
reported that plasma MGO levels are estimated to be ~0.5 µM 
in healthy subjects, and to increase to several µM in patients 
with diabetes (22,28). However, others reported that plasma 
MGO levels were in the range of ~400 µM in patients with 
poorly controlled diabetes (29). Additionally, it has been 
Figure 1. Evaluation of bone defect repair by CT scanning. (A) The recovery of bone injury lesions (drill-hole, 1.0 mm in diameter) in the left femur was 
followed and evaluated using CT scanning at days 3, 7, 10, and 14 after the bone injury. (B) Quantitative evaluation of the CT imaging of bone defect lesions. 
Cont group, non-diabetic control mice (n=6); STZ group, streptozotocin-induced diabetic mice (n=6). *P<0.05 vs. the control. Values are presented as the 
mean ± standard error of the mean. STZ, streptozotocin; HU, hounsfield unit.
Figure 2. Quantitative evaluation of AGEs in sera and femurs by LC-MS/MS. (A) Serum and (B) femur levels of the MGO-derived AGEs, CML and MG-H1, were 
measured by LC-MS/MS, as described in the Materials and methods section. The control and the STZ diabetes-induced groups both contained n=6 mice. Values 
are presented as the mean ± standard error of the mean. *P<0.05 vs. the control. MGO, methylglyoxal; AGEs, advanced glycation end-products; LC-MS/MS, 
liquid chromatography-tandem mass spectrometry; CML, Nε-(carboxymethyl)-lysine; MG-H1, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine; STZ, 
streptozotocin; Lys, lysine; Hyp, hydroxyproline.
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demonstrated that cells are able to produce large amounts 
of MGO (30), and therefore intracellular levels are probably 
much higher compared with plasma levels (31). Our hypothesis 
was therefore that the MGO concentrations used in the present 
study were neither in a non- nor a ‘super’-physiological range. 
Chan et al (32) revealed that MGO treatment (~20 µM) trig-
gered apoptotic biochemical changes in human osteoblasts. 
In addition, Suh et al (27) demonstrated that MGO toxicity 
(~400 µM) in MC3T3-E1 cells, an osteoblast-like cell line, 
was due to oxidative stress-mediated mitochondrial dysfunc-
tion (27). This oxidative stress was also able to impair 
MGO detoxification processes, with a subsequent increase 
in endogenous MGO, which, in turn, was able to potentiate 
MGO-mediated protein glycation and AGE formation, with 
Figure 3. Osteoblastic differentiation of ST2 cells in vitro. The effect of MGO on osteoblastic differentiation was examined using mouse stromal ST2 cells. 
Cells were cultured in differentiation induction media containing MGO at a final concentration of 0, 50, 200, or 400 µM. Assays for (A and B) ALP activity 
(measuring osteoblastic differentiation) and (C and D) alizarin red staining (measuring matrix mineralization) were performed at 7 and 28 days after ST2 
cell differentiation. Values are presented as the mean ± standard error of the mean. *P<0.05; **P<0.01 vs. control group. MGO, methylglyoxal; ALP, alkaline 
phosphatase.
Figure 4. Cell proliferation and cytotoxicity of ST2 cells in vitro. (A) ST2 cell proliferation was assayed using the WST-1 method (40) at 7 and 14 days after 
induction of osteoblastic differentiation with MGO at a final concentration of 0, 50, 200, or 400 µM (n=5). (B) Cytotoxicity was evaluated by release of the 
LDH enzyme into the culture media (n=4). Values are presented as the mean ± standard error of the mean. **P<0.01 vs. control group. MGO, methylglyoxal; 
LDH, lactate dehydrogenase.
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the further overproduction of reactive oxygen species (27). The 
findings of the present study, together with those of previous 
studies, suggest that MGO that accumulates under diabetic 
conditions may act on cells of the osteoblast lineage, thereby 
damaging their viability and functional differentiation.
In the present study, it was also demonstrated that bone 
repair was delayed in STZ-induced diabetic mice compared 
with non-diabetic control mice, using CT image analysis 
(Fig. 1). It is commonly known that fracture repair involves 
hematoma formation following injury, and the subsequent 
production of cytokines and growth factors, leading to inflam-
matory responses and the recruitment of mesenchymal stem 
cells (33,34). These cells proliferate and differentiate into 
chondrocytes, which subsequently form new cartilage in the 
endochondral phase. The cells along the periosteum differ-
entiate into osteoblasts to produce new bone. The cartilage 
mineralizes and mechanically stabilizes the fracture site, and 
the mineralized cartilage is subsequently removed by osteo-
clasts. The transition phase of bone formation from cartilage 
is involved in angiogenesis (33). Remodeling is the final step, 
in which osteoclasts and osteoblasts reshape the bone lesion. 
Previous studies have demonstrated that diabetes may impair 
fracture healing in almost all the above-described phases of 
fracture repair (2-4,6,7). In patients with diabetes, impaired 
recruitment of bone marrow-derived mesenchymal stem cells 
to the site of injury has been reported (35). Decreased and 
delayed bone formation was observed with the reduction of 
growth factor levels in diabetic animals (36,37). Dysregulation 
of the transition from cartilage to bone has also been observed 
due to chondrocyte apoptosis, premature removal of cartilage, 
reduced osteoblast differentiation, and insufficient vascular-
ization (7,10-12,38,39). Supernormal osteoclast activity was 
reported to disturb remodeling of the osseous callus (7). The 
drill-hole injury and recovery data featured in the present 
study were compatible with those of previous reports, clearly 
indicating that diabetes may delay and damage bone healing.
In addition, representative MGO-derived AGE levels of 
CML and MG-H1 in the sera and femurs in STZ-induced 
diabetic mice, as well as in non-diabetic control mice, were 
measured. AGE levels were significantly increased in the 
sera and femurs of diabetic mice compared with those of the 
non-diabetic controls (Fig. 2). Notably, higher levels of MG-H1 
accumulated in the femur compared with those of CML, 
whereas similar levels of the two AGEs were observed in 
sera (Fig. 2). These data suggest that the production and accu-
mulation of MGO may be upregulated, and subsequently the 
concentrations of MGO-derived AGEs may build up, thereby 
affecting biological functions in diabetes. Okazaki et al (40) 
reported that AGEs, and not high glucose exposure, were able 
to inhibit osteoblastic differentiation and mineralization of 
ST2 cells by decreasing the expression of osterix, and partly 
by increasing the expression of receptor for AGEs (RAGE). 
AGEs were also shown to inhibit cell growth and increase 
apoptosis in ST2 cells (40). CML and MG-H1 are well-known 
ligands for RAGE, and their interactions may lead to diabetic 
complications (41). Therefore, MGO in itself, and its deriva-
tives, such as AGE, all account for detrimental bone healing 
in diabetes.
Consequently, anti-glycating and quenching agents against 
reactive MGO may prove to be useful for the prevention and 
treatment of bone problems, including delayed fracture healing, 
in diabetes. The natural vitamin B6 analog, pyridoxamine, is a 
drug that may potentially be effective in diabetic nephropathy 
and retinopathy (42-51). Metformin is also a putative candi-
date (52-54). Further studies are required to investigate the 
effectiveness and application of anti-glycating remedies to 
bone problems in diabetes.
In conclusion, the present study has revealed that MGO 
was able to inhibit the differentiation and proliferation of 
osteoblasts, possibly resulting in delayed bone healing. 
Therefore, the detoxification of MGO, or of MGO scavengers, 
may improve bone repair in patients with diabetes.
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